A630018P17Rik Inhibitors
Chemical inhibitors of Transcription Elongation Factor A (SII) N-terminal and central domain containing can affect the transcription process through various mechanisms. DRB targets this protein by blocking the phosphorylation of RNA polymerase II's C-terminal domain (CTD), a crucial step in the elongation phase of transcription. Similarly, Flavopiridol acts upstream by inhibiting cyclin-dependent kinases (CDKs) that are necessary for the CTD phosphorylation, which in turn is essential for the functionality of Transcription Elongation Factor A (SII). On a more direct level, α-Amanitin binds to RNA polymerase II, impeding its ability to move along the DNA and thus stifling the elongation process. Triptolide exerts its inhibitory effect by covalently modifying subunits of RNA polymerase II, effectively shutting down the transcription machinery.
Further down the transcription pathway, Actinomycin D intercalates into DNA, obstructing RNA polymerase II from advancing and halting the elongation process. Cordycepin, by incorporating itself into the RNA chain, leads to premature termination of mRNA synthesis, thereby inhibiting the role of Transcription Elongation Factor A (SII). Inhibition can also occur indirectly through the intervention in the transcription-associated processes, as seen with ICRF-187 which chelates iron, a vital cofactor for ribonucleotide reductase, indirectly affecting transcription. Topoisomerase inhibitors like Camptothecin and Etoposide prevent the relaxation of DNA supercoils, necessary for transcription elongation, therefore indirectly affecting the function of Transcription Elongation Factor A (SII). Other compounds such as Rocaglamide, Betulinic Acid, and Silvestrol disrupt different aspects of the transcription and translation machinery, which can indirectly inhibit the function of Transcription Elongation Factor A (SII), either by affecting the initiation and elongation phases of transcription or by inducing the degradation of RNA polymerase II.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits the transcription elongation factor A (SII) N-terminal and central domain containing by obstructing the phosphorylation process of the C-terminal domain (CTD) of RNA polymerase II, a necessary step for the elongation phase of transcription where the protein plays a role. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin binds directly to RNA polymerase II and inhibits its translocation along the DNA, thus inhibiting the elongation process in which transcription elongation factor A (SII) N-terminal and central domain containing is involved. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide inhibits the overall transcription machinery by covalently modifying subunits of RNA polymerase II, preventing the transcription elongation factor A (SII) N-terminal and central domain containing from performing its function in transcription elongation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases (CDKs) which are necessary for the phosphorylation of RNA polymerase II CTD, subsequently inhibiting the action of transcription elongation factor A (SII) N-terminal and central domain containing which operates downstream of this phosphorylation. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D intercalates into DNA and prevents the transcription elongation process by RNA polymerase II, thus inhibiting the associated function of transcription elongation factor A (SII) N-terminal and central domain containing. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin causes the premature termination of mRNA synthesis by incorporating into the growing RNA chain, inhibiting the elongation function where transcription elongation factor A (SII) N-terminal and central domain containing is necessary. | ||||||
Dexrazoxane | 24584-09-6 | sc-252669 | 5 mg | $112.00 | 1 | |
ICRF-187 chelates iron, which is a cofactor required for the proper function of ribonucleotide reductase, indirectly inhibiting the transcription processes that involve the transcription elongation factor A (SII) N-terminal and central domain containing. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits topoisomerase I, which is required for relieving DNA supercoiling during transcription elongation, thereby indirectly inhibiting the function of transcription elongation factor A (SII) N-terminal and central domain containing. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide inhibits topoisomerase II, preventing the relaxation of DNA supercoils and thus indirectly inhibiting the transcription elongation process in which transcription elongation factor A (SII) N-terminal and central domain containing is involved. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide inhibits the initiation and elongation phases of transcription by binding to eIF4A and disrupting its interaction with RNA, which can inhibit the functions of proteins involved in elongation, such as transcription elongation factor A (SII) N-terminal and central domain containing. | ||||||